{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 8 of 52', '10. A female patient of child-bearing potential must be non-', 'pregnant and non-lactating and have negative pregnancy tests', 'at the Screening Visit and on Day 1 prior to dosing with study', 'drug.', '11. Patients must be able to understand and be willing to sign the', 'written informed consent form. A signed informed consent', 'form must be appropriately obtained prior to the conduct of', 'any trial-specific procedure.', '12. Willing and able to comply with the protocol, including follow-', 'up visits and examinations.', 'Main Exclusion Criteria', '1. Patient has loose (mushy) or watery stools for > 25% of their', 'bowel movements (BMs) during the 12 weeks before Screening', 'or during the Screening and Pre-treatment Periods.', '2.', 'Patient has a history of cathartic colon, laxative, or enema', 'abuse.', '3.', 'Patient has a history of ischemic colitis.', '4. Patient has a history of pelvic floor dysfunction.', '5. Patient has a history of bariatric surgery for the treatment of', 'obesity.', '6. Patient has a history of surgery to remove a segment of the', 'gastrointestinal (GI) tract at any time before the Screening', 'Visit.', '7. Patient has any history of myopathy, rhabdomyolysis, chronic', 'myalgia, or familial history of hereditary muscular disorders.', '8.', 'Patient has been diagnosed with or has a family history of', 'familial adenomatous polyposis, hereditary nonpolyposis', 'colorectal cancer, or any other form of familial colorectal', 'cancer.', '9.', 'Patient currently has any structural abnormality of the GI tract', 'or a disease or condition that can affect GI motility, or any', 'unexplained and clinically significant symptoms such as lower', 'GI bleeding, rectal bleeding, heme-positive stool, iron-', 'deficiency anemia, weight loss, or systemic signs of infection.', '10. Patient has had any previous surgery involving the abdomen,', 'pelvis, or retroperitoneal region during the last 12 months', 'prior to Screening, with the exclusion of laparoscopic', 'gallbladder surgery or appendix removal.', '11. Patient has a history of diverticulitis or any chronic condition', 'that could be associated with abdominal pain or discomfort', 'and could confound the assessments in the study (e.g.', 'inflammatory bowel disease, chronic pancreatitis, polycystic', 'kidney disease, ovarian cysts, endometriosis, or lactose', 'intolerance).']['Date: June 30, 2020', 'Version: 8.0', 'Page: 9 of 52', '12. Patient has history of severe renal insufficiency defined as an', 'actual or estimated glomerular filtration rate of < 30', 'mL/min/1.73 m\u00b2 within the 6 months prior to Screening Visit.', '13. Patient has any history of a medical condition or a concomitant', 'medical condition that, in the opinion of the investigator,', \"would compromise the patient's ability to complete the study\", 'safely or could confound the assessments in this study (e.g.', 'uncontrolled hypothyroidism).', '14. Patient is known to have elevated liver enzyme levels', '(aspartate aminotransferase [AST], alanine aminotransferase', '[ALT], alkaline phosphatase [ALP]) or creatine kinase levels that', 'are 1.5 times the upper limit of normal (ULN) that have not', 'been resolved within the 4 weeks prior to consent and/or', 'these elevated levels are present at the Screening Visit', 'laboratory assessment.', '15. Patient has any abnormal laboratory results, electrocardiogram', '(ECG) findings, or physical examination findings deemed', 'clinically significant by the investigator during the Screening', 'Period.', '16. Within 14 days prior to the Screening Visit, patient has used', 'concomitant medications that are: (1) moderate-to-strong', 'inhibitors of cytochrome P450 3A (CYP3A) and/or organ anion', 'transporting polypeptide (OATP)1B (e.g. cyclosporine,', 'verapamil, dronedarone, diltiazem, amiodarone, itraconazole,', 'ketoconazole, posaconazole, voriconazole, clarithromycin,', 'telithromycin, human immunodeficiency virus protease', 'inhibitors, boceprevir, telaprevir, nefazodone, erythromycin,', 'cobicistat-containing products); (2) other concomitant', 'medications that are excluded from the lovastatin label (e.g.', 'rifampin, colchicine, ranolazine); or (3) metformin or GLP-1', 'agonists. Patients should not take any of these concomitant', 'medications during the treatment phase of the study without', 'contacting the investigator.', '17. Patient has hypersensitivity to statins; or has used any statins,', 'fibrates, > 1 g/day of niacin, or gemfibrozil within the 3 months', 'prior to the Screening Visit.', '18. Patient reports current chronic or frequent use of drugs known', 'to cause constipation (e.g. narcotics) for the 3 months prior to', 'Screening.', '19. Patient has taken over-the-counter IBS treatments (e.g.', 'laxatives) or proton pump inhibitors within 3 days prior to the', 'Screening Visit.', '20. Certain drugs used for the treatment of IBS (e.g. low dose', 'tricyclic antidepressants) may be allowed at the discretion of', 'the Medical Monitor provided the patient remains on a stable', 'dose for one month prior to the Screening Visit and throughout', 'the study with the exception of tegaserod, lubiprostone,']\n\n###\n\n", "completion": "END"}